iRhythm Holdings, Inc. reports developments for a digital health care business focused on ambulatory cardiac monitoring and arrhythmia detection. The company’s recurring updates center on the Zio ambulatory ECG portfolio, which combines patch-based monitoring, AI-powered analysis, and clinical data review to deliver cardiac rhythm insights to physicians.
Company news commonly covers quarterly and annual financial results, revenue guidance, margin trends, and operating leverage, along with clinical evidence presented at cardiology meetings. Other updates include clinician education initiatives, investor conference participation, board and governance changes, and the company’s completed transition to a holding-company structure as successor registrant to iRhythm Technologies.
iRhythm Technologies (NASDAQ: IRTC) announced Q3 2022 financial results with revenues of $103.9 million, a 21.6% increase compared to Q3 2021. Gross margin improved to 68.3%. However, due to staffing challenges and device returns, the company updated its annual revenue guidance to between $407 million to $411 million, down from a prior estimate of $415 million to $420 million. Despite challenges, iRhythm reported a lower adjusted net loss of $19.1 million compared to $23.7 million in Q3 2021.
iRhythm Technologies, Inc. (NASDAQ: IRTC) will announce its third quarter 2022 financial results on November 1, 2022, after market close. A conference call is scheduled for 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. iRhythm specializes in digital healthcare solutions that utilize wearable biosensors and cloud-based analytics to provide actionable insights from heart data. This approach aims to improve patient care by delivering better data and health outcomes.
iRhythm Technologies (NASDAQ: IRTC) announced its strategies for long-term growth during the 2022 Analyst & Investor Day in New York City. CEO Quentin Blackford highlighted a vision for $1 billion in revenue by 2027, driven by a 30% CAGR from 2022 guidance of $415-$420 million. The company's 2022 guidance includes a gross margin of 68%-69% and projected adjusted EBITDA losses of $12.5 million to $17.5 million. iRhythm aims for a 15% adjusted EBITDA margin by 2027, with significant international market opportunities and operational excellence initiatives anticipated to yield over $250 million in annual savings.
iRhythm Technologies (NASDAQ: IRTC) will host an Analyst & Investor Day on September 21, 2022, in New York City. The event will begin at 9:00 a.m. ET and will be available via live webcast on the company’s investor website. A replay and additional materials will be accessible post-event.
iRhythm, a leader in digital healthcare, focuses on advancing cardiac care through wearable biosensors and cloud-based analytics, aiming to enhance arrhythmia detection and clinical management of patients.
iRhythm Technologies reported strong second quarter results for 2022, achieving $102.1 million in revenue, a 25.6% increase year-over-year. The gross margin improved to 68.8%, alongside a significant rise in gross profit to $70.2 million. Despite a net loss of $23.9 million or $0.80 per share, the company raised its full-year revenue guidance to between $415 million and $420 million. iRhythm continues to expand its executive team and aims to grow its market presence with innovations like the Zio Watch and increased Medicare pricing.
iRhythm Technologies (NASDAQ:IRTC) has announced its participation in the Canaccord Genuity 42nd Annual Growth Stock Conference on August 11, 2022, at 12:00 p.m. Eastern Time. The company, known for its innovative cardiac care solutions, will provide a live and archived webcast of the presentation on its website. iRhythm specializes in diagnosing cardiac arrhythmias through wearable biosensor devices and advanced data analytics, aiming to enhance patient management through improved arrhythmia detection.
iRhythm Technologies (NASDAQ:IRTC) announced leadership changes, appointing Brice Bobzien as Chief Financial Officer starting August 8, 2022, and Reyna Fernandez as Executive Vice President, Chief Human Resources Officer on July 25, 2022. Bobzien, previously at Dexcom, will focus on financial operations and growth, while Fernandez will drive HR strategies for global expansion. iRhythm aims to enhance operational effectiveness and efficiency with these appointments, aligning with its vision to lead in digital healthcare for cardiac care.
iRhythm Technologies has received FDA 510(k) clearance for its ZEUS System in conjunction with the Zio Watch, developed with Verily. This clinical-grade wearable aims to detect and monitor atrial fibrillation (AFib), integrating seamlessly into clinician workflows. The Zio Watch employs advanced algorithms for continuous monitoring and generating preliminary reports for physicians. Notably, the ACE algorithm achieved a 93.6% sensitivity and 99.1% specificity for AFib detection. The Zio Watch will be evaluated in a limited market in 2023.
iRhythm Technologies, Inc. (NASDAQ: IRTC) announced the resignation of Chief Commercial Officer Dave Vort, effective July 25, 2022. Vort will continue as a strategic advisor until March 31, 2023. Chad Patterson, formerly Chief Marketing Officer at Dexcom, joins as the new CCO. iRhythm estimates preliminary unit volumes for Q2 2022 are slightly ahead of expectations, with projected revenue for the year between $410 million and $420 million. The company will release its Q2 2022 financial results on August 4, 2022.
iRhythm Technologies (NASDAQ: IRTC) commented on the CMS Medicare Physician Fee Schedule Proposed Rule for 2023, released on July 7, 2022. The proposed rule includes updates to payment rates for long-term ECG monitoring services, specifically through CPT codes 93243 and 93247, used for reimbursement of the Zio XT service. Proposed national payment rates are $215 and $204, with potential rates ranging from $218 to $295 and $207 to $280 depending on geographic factors. iRhythm anticipates the impact on its full-year 2022 revenue guidance would be immaterial.